Vince Bertucci, MD, FRCPC: Bertucci MedSpa
8333 Weston Road, Suite 100
Woodbridge, ON L4L 8E2
Phone: (905) 850-4415
Hours: Monday: 8 a.m.–5 p.m.
Tuesday: 9 a.m.–5 p.m.
Wednesday – Thursday: 8 a.m.–5 p.m.
Friday: 8 a.m.–4 p.m.
- A randomized, evaluator-blinded, parallel group, no treatment controlled, multicentre study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region (Concluded: 2022)
- A Prospective, Single blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers (Concluded: 2021)
- Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane (CHEEKY Study) (Concluded: 2021)
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines (Concluded: 2021)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (READY – 3) (Concluded: 2021)
- A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence (Concluded: 2020)
- A Phase 2a, Multicenter, Open-Label, Dose-EscalationStudy to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections (Concluded: 2020)